Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Frederik Persson; Maria Nicolaides; Alexia Richard; Zhihua Xiang; Juergen Armbrecht; Marc A Pfeffer; ALTITUDE Investigators

doi:10.1177/1470320311434818

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

Hans-Henrik Parving
, Barry M Brenner
, John J V McMurray
, Dick de Zeeuw
, Steven M Haffner
, Scott D Solomon
, Nish Chaturvedi
, Frederik Persson
, Maria Nicolaides
, Alexia Richard
, Zhihua Xiang
, Juergen Armbrecht
, Marc A Pfeffer
, ALTITUDE Investigators

61 Citationer (Scopus)

Abstract

Patients with type 2 diabetes are at enhanced risk for macro- and microvascular complications. Albuminuria and/or reduced kidney function further enhances the vascular risk. We initiated the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). Aliskiren, a novel direct renin inhibitor, which lowers plasma renin activity, may thereby provide greater cardio-renal protection compared with angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) alone.

Originalsprog	Engelsk
Tidsskrift	Journal of the Renin-Angiotensin-Aldosterone System
Vol/bind	13
Udgave nummer	3
Sider (fra-til)	387-93
Antal sider	7
ISSN	1470-3203
DOI	https://doi.org/10.1177/1470320311434818
Status	Udgivet - 2012

Adgang til dokumentet

10.1177/1470320311434818

Citationsformater

Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Nicolaides, M., Richard, A., Xiang, Z., Armbrecht, J., Pfeffer, M. A., & ALTITUDE Investigators (2012). Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). Journal of the Renin-Angiotensin-Aldosterone System, 13(3), 387-93. https://doi.org/10.1177/1470320311434818

Parving, H-H, Brenner, BM, McMurray, JJV, de Zeeuw, D, Haffner, SM, Solomon, SD, Chaturvedi, N, Persson, F, Nicolaides, M, Richard, A, Xiang, Z, Armbrecht, J, Pfeffer, MA & ALTITUDE Investigators 2012, 'Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)', Journal of the Renin-Angiotensin-Aldosterone System, bind 13, nr. 3, s. 387-93. https://doi.org/10.1177/1470320311434818

@article{cb40efc05ce242f0bb0bbf8d18214a3b,

title = "Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)",

abstract = "Patients with type 2 diabetes are at enhanced risk for macro- and microvascular complications. Albuminuria and/or reduced kidney function further enhances the vascular risk. We initiated the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). Aliskiren, a novel direct renin inhibitor, which lowers plasma renin activity, may thereby provide greater cardio-renal protection compared with angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) alone.",

author = "Hans-Henrik Parving and Brenner, \{Barry M\} and McMurray, \{John J V\} and \{de Zeeuw\}, Dick and Haffner, \{Steven M\} and Solomon, \{Scott D\} and Nish Chaturvedi and Frederik Persson and Maria Nicolaides and Alexia Richard and Zhihua Xiang and Juergen Armbrecht and Pfeffer, \{Marc A\} and \{ALTITUDE Investigators\}",

year = "2012",

doi = "10.1177/1470320311434818",

language = "English",

volume = "13",

pages = "387--93",

journal = "Journal of the Renin-Angiotensin-Aldosterone System",

issn = "1470-3203",

publisher = "SAGE Publications Ltd",

number = "3",

}

TY - JOUR

T1 - Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

AU - Parving, Hans-Henrik

AU - Brenner, Barry M

AU - McMurray, John J V

AU - de Zeeuw, Dick

AU - Haffner, Steven M

AU - Solomon, Scott D

AU - Chaturvedi, Nish

AU - Persson, Frederik

AU - Nicolaides, Maria

AU - Richard, Alexia

AU - Xiang, Zhihua

AU - Armbrecht, Juergen

AU - Pfeffer, Marc A

AU - ALTITUDE Investigators

PY - 2012

Y1 - 2012

N2 - Patients with type 2 diabetes are at enhanced risk for macro- and microvascular complications. Albuminuria and/or reduced kidney function further enhances the vascular risk. We initiated the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). Aliskiren, a novel direct renin inhibitor, which lowers plasma renin activity, may thereby provide greater cardio-renal protection compared with angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) alone.

AB - Patients with type 2 diabetes are at enhanced risk for macro- and microvascular complications. Albuminuria and/or reduced kidney function further enhances the vascular risk. We initiated the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). Aliskiren, a novel direct renin inhibitor, which lowers plasma renin activity, may thereby provide greater cardio-renal protection compared with angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) alone.

U2 - 10.1177/1470320311434818

DO - 10.1177/1470320311434818

M3 - Journal article

C2 - 22333485

SN - 1470-3203

VL - 13

SP - 387

EP - 393

JO - Journal of the Renin-Angiotensin-Aldosterone System

JF - Journal of the Renin-Angiotensin-Aldosterone System

IS - 3

ER -

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater